Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

TG Therapeutics, Inc. TGTX

Healthcare  —  Biotechnology
57.43 (0.09) (0.16%) as of 25 Sep
Market cap
$8.8B
P/E
18.9×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

TG Therapeutics, Inc. (TGTX) Business Profile

Updated before January 2025

Company Overview

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company dedicated to developing and delivering innovative treatments for B-cell diseases, including cancers and autoimmune disorders. Founded in 2012 and headquartered in New York City, TG Therapeutics has established itself as a key player in the biotechnology sector. The company was co-founded by Michael S. Weiss, who serves as the Executive Chairman and Chief Executive Officer. Weiss brings decades of experience in the biotech and pharmaceutical industries, driving the company’s strategic vision and operational execution. TG Therapeutics is committed to improving patient outcomes through the development of novel therapies that address unmet medical needs.

Core Business Segments

TG Therapeutics focuses on the development and commercialization of therapies targeting B-cell malignancies and autoimmune diseases. The company’s core business segments include:

1. Oncology

TG Therapeutics has developed a robust pipeline of therapies aimed at treating B-cell cancers such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). Key products include:

  • Ublituximab (BRUKINSA®): A monoclonal antibody targeting CD20, designed to enhance the immune system’s ability to attack cancer cells. Ublituximab has shown promising results in clinical trials for CLL and NHL.
  • Umbralisib (UKONIQ®): A PI3K delta inhibitor approved for the treatment of relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib is part of TG Therapeutics’ dual mechanism approach to targeting B-cell malignancies.

2. Autoimmune Diseases

TG Therapeutics is also advancing therapies for autoimmune disorders, leveraging its expertise in B-cell biology. The company is exploring the use of ublituximab in treating multiple sclerosis (MS) and other autoimmune conditions.

3. Combination Therapies

Recognizing the potential of combination therapies, TG Therapeutics is developing regimens that combine its proprietary drugs to enhance efficacy and improve patient outcomes. For example, the U2 regimen (ublituximab and umbralisib) has been studied for its effectiveness in treating CLL and other B-cell malignancies.

Business Model

TG Therapeutics operates on a research-driven business model, focusing on the discovery, development, and commercialization of innovative therapies. The company generates revenue primarily through the sale of its approved products, such as umbralisib, and through partnerships and licensing agreements. TG Therapeutics invests heavily in clinical trials and regulatory approvals to expand the indications for its existing products and bring new therapies to market. The company’s integrated approach combines in-house research capabilities with strategic collaborations to accelerate drug development and commercialization.

Strategic Direction

TG Therapeutics is committed to expanding its portfolio of therapies and addressing unmet medical needs in oncology and autoimmune diseases. Key strategic priorities include:

  • Pipeline Expansion: The company is actively pursuing additional indications for its existing products and developing new therapies targeting B-cell diseases.
  • Global Market Penetration: TG Therapeutics aims to expand its presence in international markets by securing regulatory approvals and establishing distribution partnerships.
  • Sustainability Goals: While not a primary focus, TG Therapeutics is exploring ways to minimize its environmental impact through sustainable manufacturing practices and supply chain optimization.
  • Innovation in Combination Therapies: The company continues to invest in the development of combination regimens to improve treatment outcomes and reduce side effects.

Competitive Landscape

TG Therapeutics operates in a highly competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Roche: A global leader in oncology, offering therapies such as Rituxan® and Gazyva® for B-cell malignancies.
  • AbbVie: Known for its blockbuster drug Imbruvica®, which targets B-cell cancers.
  • Bristol-Myers Squibb: A major player in immuno-oncology with a diverse portfolio of cancer therapies.
  • Novartis: Competes in the autoimmune disease space with therapies like Cosentyx®.

TG Therapeutics differentiates itself through its focus on innovative combination therapies and its commitment to addressing unmet medical needs.

Risk Factors

Like any biopharmaceutical company, TG Therapeutics faces several risks, including:

  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for new products or indications could impact the company’s growth.
  • Market Dependence: The company relies heavily on the success of its key products, such as umbralisib and ublituximab. Any setbacks in these products could significantly affect revenue.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes TG Therapeutics to potential disruptions that could delay product availability.
  • Competitive Pressure: Intense competition from larger pharmaceutical companies with greater resources poses a constant challenge.
  • Clinical Trial Risks: The success of TG Therapeutics’ pipeline depends on the outcomes of clinical trials, which are inherently uncertain.

Recent Developments

TG Therapeutics has made significant strides in recent years, including:

  • FDA Approvals: The company received FDA approval for umbralisib (UKONIQ®) for the treatment of MZL and FL, marking a major milestone in its commercialization efforts.
  • Clinical Trial Progress: TG Therapeutics has reported positive results from late-stage clinical trials for its U2 regimen in treating CLL.
  • Strategic Partnerships: The company has entered into collaborations with academic institutions and research organizations to advance its pipeline.
  • Impact of Global Events: The COVID-19 pandemic posed challenges to clinical trial timelines and supply chain operations, but TG Therapeutics has demonstrated resilience in navigating these disruptions.

Investment Considerations

Strengths:

  • Innovative Pipeline: TG Therapeutics has a strong pipeline of therapies targeting high-value markets in oncology and autoimmune diseases.
  • Experienced Leadership: The company benefits from the expertise of its CEO, Michael Weiss, and a seasoned management team.
  • Focus on Unmet Needs: TG Therapeutics addresses significant gaps in treatment options for B-cell diseases.

Risks:

  • Regulatory and Clinical Uncertainty: The success of the company’s pipeline depends on regulatory approvals and clinical trial outcomes.
  • Market Competition: TG Therapeutics faces competition from well-established players with greater resources.
  • Financial Risks: As a relatively small biopharmaceutical company, TG Therapeutics may face challenges in securing funding for its operations and pipeline development.

Conclusion

TG Therapeutics, Inc. is a dynamic biopharmaceutical company with a strong focus on developing innovative therapies for B-cell diseases. With a robust pipeline, experienced leadership, and a commitment to addressing unmet medical needs, the company is well-positioned for growth. However, investors should carefully consider the risks associated with regulatory challenges, market competition, and financial sustainability. Overall, TG Therapeutics represents a compelling opportunity for those seeking exposure to the biotechnology sector.